NO341663B1 - Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer - Google Patents

Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer

Info

Publication number
NO341663B1
NO341663B1 NO20084637A NO20084637A NO341663B1 NO 341663 B1 NO341663 B1 NO 341663B1 NO 20084637 A NO20084637 A NO 20084637A NO 20084637 A NO20084637 A NO 20084637A NO 341663 B1 NO341663 B1 NO 341663B1
Authority
NO
Norway
Prior art keywords
indolobenzzaepine
cyclopropyl
condensed
hcv ns5b
ns5b inhibitors
Prior art date
Application number
NO20084637A
Other languages
English (en)
Other versions
NO20084637L (no
Inventor
John A Bender
Min Ding
Robert G Gentles
Piyasena Hewawasam
Original Assignee
Bristol Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38512732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO341663(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Holdings Ireland filed Critical Bristol Myers Squibb Holdings Ireland
Publication of NO20084637L publication Critical patent/NO20084637L/no
Publication of NO341663B1 publication Critical patent/NO341663B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen omfatter forbindelser med formel I så vel som preparater og metoder for anvendelse av forbindelsene. Forbindelsene har aktivitet mot hepatitt C virus (HCV) og er anvendelige for behandling av de som er infisert med HCV.
NO20084637A 2006-05-17 2008-11-04 Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer NO341663B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80112506P 2006-05-17 2006-05-17
US80200506P 2006-05-19 2006-05-19
US85208406P 2006-10-16 2006-10-16
US89475707P 2007-03-14 2007-03-14
PCT/US2007/068209 WO2007136982A1 (en) 2006-05-17 2007-05-04 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Publications (2)

Publication Number Publication Date
NO20084637L NO20084637L (no) 2008-12-15
NO341663B1 true NO341663B1 (no) 2017-12-18

Family

ID=38512732

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084637A NO341663B1 (no) 2006-05-17 2008-11-04 Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer

Country Status (25)

Country Link
US (1) US7456166B2 (no)
EP (1) EP2024375B1 (no)
JP (1) JP5284952B2 (no)
KR (1) KR101417145B1 (no)
AR (1) AR061008A1 (no)
AT (1) ATE501156T1 (no)
AU (1) AU2007253998B2 (no)
BR (1) BRPI0711821A2 (no)
CA (1) CA2651690C (no)
CY (1) CY1111526T1 (no)
DE (1) DE602007013036D1 (no)
DK (1) DK2024375T3 (no)
EA (1) EA015286B1 (no)
HK (1) HK1122814A1 (no)
HR (1) HRP20110194T1 (no)
IL (1) IL195025A (no)
MX (1) MX2008014435A (no)
NO (1) NO341663B1 (no)
NZ (1) NZ572555A (no)
PE (1) PE20080070A1 (no)
PL (1) PL2024375T3 (no)
SI (1) SI2024375T1 (no)
TW (1) TWI401244B (no)
WO (1) WO2007136982A1 (no)
ZA (1) ZA200809548B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688420A4 (en) * 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2343914T3 (es) * 2006-05-25 2010-08-12 Bristol-Myers Squibb Company Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo.
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
WO2008111978A1 (en) 2007-03-13 2008-09-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN102872461A (zh) 2007-05-04 2013-01-16 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
PL2209789T3 (pl) * 2007-11-20 2012-04-30 Bristol Myers Squibb Co Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2710644C (en) 2007-12-24 2016-03-29 Tibotec Pharmaceuticals Macrocyclic indoles as hepatitis c virus inhibitors
EP2268643B1 (en) * 2008-03-27 2014-08-06 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors
MX2010010061A (es) * 2008-03-27 2010-09-30 Bristol Myers Squibb Co Compuestos para el tratamiento de hepatitis c.
EP2280978B1 (en) * 2008-03-27 2013-04-24 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
SG172848A1 (en) 2009-01-07 2011-08-29 Scynexis Inc Cyclosporine derivative for use in the treatment of hcv and hiv infection
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
AU2011268922B2 (en) 2010-06-24 2014-06-12 Janssen Sciences Ireland Uc Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
AU2011352145A1 (en) 2010-12-30 2013-07-18 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
AU2013290402A1 (en) 2012-07-18 2015-03-05 Bristol-Myers Squibb Holdings Ireland Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020082A1 (en) * 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2006046030A2 (en) * 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US752354A (en) * 1904-02-16 Composition post
US753137A (en) * 1904-02-23 Dust-pan
US756203A (en) * 1903-11-14 1904-04-05 Oliver E Barthel Muffler.
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7348425B2 (en) * 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2006040039A1 (de) 2004-10-13 2006-04-20 Merck Patent Gmbh Als kinaseinhibitoren geeignete derivate des n, n ´ -diphenylharnstoffs
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) * 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020082A1 (en) * 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2006046030A2 (en) * 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents

Also Published As

Publication number Publication date
CY1111526T1 (el) 2016-02-10
ATE501156T1 (de) 2011-03-15
JP2009537557A (ja) 2009-10-29
AR061008A1 (es) 2008-07-30
MX2008014435A (es) 2008-11-27
HRP20110194T1 (hr) 2011-04-30
KR101417145B1 (ko) 2014-07-08
EA200802346A1 (ru) 2009-06-30
DE602007013036D1 (de) 2011-04-21
IL195025A0 (en) 2009-08-03
EP2024375B1 (en) 2011-03-09
CA2651690C (en) 2014-11-04
NO20084637L (no) 2008-12-15
SI2024375T1 (sl) 2011-10-28
PL2024375T3 (pl) 2011-07-29
PE20080070A1 (es) 2008-03-10
US7456166B2 (en) 2008-11-25
ZA200809548B (en) 2009-12-30
AU2007253998B2 (en) 2012-03-15
US20070270405A1 (en) 2007-11-22
NZ572555A (en) 2010-11-26
EA015286B1 (ru) 2011-06-30
KR20090008344A (ko) 2009-01-21
WO2007136982A1 (en) 2007-11-29
TW200804282A (en) 2008-01-16
AU2007253998A1 (en) 2007-11-29
TWI401244B (zh) 2013-07-11
IL195025A (en) 2013-09-30
BRPI0711821A2 (pt) 2012-01-17
HK1122814A1 (en) 2009-05-29
DK2024375T3 (da) 2011-06-27
JP5284952B2 (ja) 2013-09-11
CA2651690A1 (en) 2007-11-29
EP2024375A1 (en) 2009-02-18

Similar Documents

Publication Publication Date Title
NO341663B1 (no) Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer
NO20084645L (no) Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer
ATE483712T1 (de) Hcv-ns5b-inhibitoren
EA200901101A1 (ru) Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс
NO20092053L (no) HCV NS3-proteaseinhibitorer
NO20091591L (no) Hepatitt C virusinhibitorer
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
EA201170241A1 (ru) Макроциклические хиноксалиновые соединения в качестве ингибиторов протеазы вгс ns3
EA200800371A1 (ru) Ингибиторы ns3 протеазы вгс
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
NO20073849L (no) Indolderivater for behandling av virale infeksjoner
NO20070751L (no) Inhibitorer av HCV-replifikasjon
NO20091845L (no) Macrocykliske peptider som hepatitt C virus-inhibitorer
NO20082934L (no) Antivirale nukleotider
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
NO20091707L (no) Inhibitorer av hepatitt C virus
NO20091704L (no) Inhibitorer av hepatitt C virus
NO20091846L (no) Makrocykliske peptider som hepatitt C virus- inhibitorer
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
WO2009029384A3 (en) Compounds for the treatment of hepatitis c

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMI, CH

MM1K Lapsed by not paying the annual fees